Compare TKLF & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | COCP |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 14.1M |
| IPO Year | 2022 | N/A |
| Metric | TKLF | COCP |
|---|---|---|
| Price | $2.50 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 10.7K | ★ 58.8K |
| Earning Date | 12-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $210,119,238.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | ★ 7.38 | N/A |
| 52 Week Low | $2.10 | $0.90 |
| 52 Week High | $4.32 | $3.26 |
| Indicator | TKLF | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 46.88 |
| Support Level | $2.35 | $1.01 |
| Resistance Level | $2.63 | $1.10 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 59.70 | 57.00 |
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).